Why I Think This Stock is Worth 3x the Current Price
Insperity's healthcare-cost spike, $120 million technology expense and weak SMB hiring drove its 70% drawdown; normalized earnings could…
Monday, April 27
Monday, April 27, 2026
Everything we published on this day.
5 stories
Buyout Update for Hidden Rock Capital Names
RE/MAX’s $13.80-per-share Real Brokerage offer is capped at $80 million cash, implying roughly $11.40 of value at REAX’s $2.02 share price.
marginofdanger on X
Ackman's closed end fund $PSUS will begin trading on Wednesday. For every 5 shares of PSUS, IPO investors (only) will get 1 share of $PS (the GP). It sounds like the PSUS offering will be 100mm shares at $50/share or $5 bn. Ackman thought this was going to be a $10 bn offering and he previously was targeting $25 bn or some ridiculous amount. The PSUS IPO investors will end up owning 20mm shares or 5% of PS (based on 400mm pf s/o). I expect that PSUS, like many closed end funds, will settle at a 5-10% discount to NAV, implying a trading price of $45-47.50/share. PS will begin trading as well (via a direct listing) and I anticipate a valuation of $5-10bn, implying that the PSUS IPO investors will get a "bonus" of $250-500mm on the $5 bn IPO or 5-10%. Therefore their loss on the PSUS shares should be mostly offset by the free shares in PS. Given this is a direct listing, I expect WILD price movements in PS stock and would stay far away from that one. I used $10 bn as the high end valuation for PS because that is where investors invested back a year or so ago (predicated upon significant growth in AUM), but I tend to believe that was a high watermark and not realistic given that Ackman can't seem to raise $. In terms of $PSUS, I don't see a compelling reason to own this at 90-95% of NAV. If you put a 15x on the 2% fee, that alone is a 30% drag. Also, Ackman has high volatility and there is no prospect to ever get repaid (and no incentive for Ackman to do so). Like $PSH.LN I would personally only step into $PSUS at a 25-30%+ discount to NAV and probably not in any real size.
CDLR · long Cadeler A/S
Cadeler (CDLR) is the world’s largest pure-play owner-operator of wind turbine installation vessels, listed in Oslo and on the NYSE.
KHTRF · long Knight Therapeutics INC
Knight Therapeutics (GUD-T) is a long position built on confidence in founder Jonathan Goodman, following his earlier success with Paladin…
